CRL (Charles River Laboratories International) Other Current Liabilities: $393 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRL Charles River Laboratories International Inc CRL
70 GF Score
Price $219.40
GF Value $194.04
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Charles River Laboratories International Other Current Liabilities?

Charles River Laboratories International CRL -0.14% 70 Other Current Liabilities is $393 Mil as of Mar. 2026. GuruFocus rates CRL with a GF Score™ of 70/100 and a GF Value™ of $194.04 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Charles River Laboratories International's other current liabilities for the quarter that ended in Mar. 2026 was $393 Mil.

Charles River Laboratories International's quarterly other current liabilities increased from Sep. 2025 ($486 Mil) to Dec. 2025 ($491 Mil) but then declined from Dec. 2025 ($491 Mil) to Mar. 2026 ($393 Mil).

Charles River Laboratories International's annual other current liabilities declined from Dec. 2023 ($417 Mil) to Dec. 2024 ($373 Mil) but then increased from Dec. 2024 ($373 Mil) to Dec. 2025 ($491 Mil).

Charles River Laboratories International Other Current Liabilities Related Terms

Charles River Laboratories International Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Charles River Laboratories International's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Charles River Laboratories International Other Current Liabilities Chart

Charles River Laboratories International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 386.56 401.65 416.50 373.43 491.01

Charles River Laboratories International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 408.79 434.73 485.65 491.01 393.03
CRL
70GF Score
Charles River Laboratories International Inc CRL
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Charles River Laboratories International Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $393 Mil mean?
Charles River Laboratories International (CRL) has a Other Current Liabilities of $393 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Charles River Laboratories International.
Is Charles River Laboratories International's Other Current Liabilities too high?
Charles River Laboratories International's current Other Current Liabilities is $393 Mil. Overall, Charles River Laboratories International has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's Other Current Liabilities compare to RVTY and QGEN?
Charles River Laboratories International's Other Current Liabilities of $393 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Diagnostics & Research company?
A good Other Current Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Charles River Laboratories International. Charles River Laboratories International's current Other Current Liabilities is $393 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (CRL) is currently considered Modestly Overvalued. The stock's GF Value™ is $194.04, compared to a current price of $219.40 — trading 13.1% above its estimated fair value. The current Other Current Liabilities is $393 Mil. Charles River Laboratories International's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Charles River Laboratories International (CRL), the current Other Current Liabilities is $393 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Charles River Laboratories International (CRL) Overvalued in 2026?

Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued. The current stock price of $219.40 is trading 13.1% above its estimated GF Value™ of $194.04. GuruFocus considers Charles River Laboratories International to be Modestly Overvalued.

Key valuation signals for CRL:

  • Other Current Liabilities: $393 Mil
  • GF Value™: $194.04 vs. price of $219.40 (13.1% above fair value)
  • GF Score™: 70/100 with 8 warning signs

No single metric tells the full story. See the CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Charles River Laboratories International Business Description

Other Exchanges RV6:Germany
Address 251 Ballardvale Street, Wilmington, MA, USA, 01887
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
70GF Score

Get the complete analysis for CRL

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$219.40
Price
$194.04
GF Value